LYON, France, July 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
LYON, France and CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 26, 2020. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor
Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached LYON,France and CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a
LYON, France, June 09, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
Patient enrollment completed; 50 patients in the trial Encouraging preliminary results based on interim data Unmet medical need confirmed by FDA LYON, France and CAMBRIDGE, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company
LYON, France and CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil BEYEN, Chief
LYON, France and CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the presentation of two posters at
Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting LYON, France, May 26, 2020 (GLOBE NEWSWIRE) -- Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical
LYON, France, May 07, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 Trial: More than 75% of the planned ~ 500 patients enrolled Fast-Drack designation granted by U.S. FDA Trial to continue as planned after third independent safety review Interim superiority analysis expected
